RNA
Atrium Therapeutics, Inc.
7.50$
+0.1%
vs. previous close
Closing price · As of: Nov 13, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Atrium Therapeutics, Inc. (RNA) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 11/12/2026 | Current report (8-K) | Atrium Therapeutics, Inc. (RNA): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
| 11/02/2026 | Current report (8-K) | Atrium Therapeutics, Inc. (RNA): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View report ↗ |
| 10/27/2026 | Current report (8-K) | Atrium Therapeutics, Inc. (RNA): Other Events; Financial Statements and Exhibits | View report ↗ |
| 10/08/2026 | Current report (8-K) | Atrium Therapeutics, Inc. (RNA): Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View report ↗ |
| 08/14/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 08/13/2026 | Current report (8-K) | Atrium Therapeutics, Inc. (RNA): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.